Connect
MJA
MJA

Prevention of cardiovascular disease: an evidence-based clinical aid

Gregory R Fulcher, John V Amerena and Greg W Conner
Med J Aust 2004; 180 (4): . || doi: 10.5694/j.1326-5377.2004.tb05874.x
Published online: 16 February 2004

Gregory R Fulcher,* John V Amerena, Greg W Conner


  • 1 Department of Diabetes, Endocrinology and Metabolic Medicine, Level 3, Main Block, Royal North Shore Hospital, St Leonards, NSW 2065
  • 2 Department of Clinical and BioMedical Sciences, University of Melbourne, Melbourne, VIC
  • 3 Cardiovascular Diagnostic Services, Sydney, NSW.


Correspondence: gfulcher@med.usyd.edu.au

  • 1. Fulcher GR, Conner GW, Amerena JV, et al. Prevention of cardiovascular disease: an evidence-based clinical aid [Focus document]. Med J Aust 2003; 179 (21 July): 1-16. <eMJA full text> <MJA full text>
  • 2. Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the US Preventive Services Task Force. Ann Intern Med 2002; 136: 161-172.
  • 3. Hung J, for the Medical Issues Committee of the National Heart Foundation of Australia. Aspirin for cardiovascular disease prevention [position statement]. Med J Aust 2003; 179: 147-152. <eMJA full text> <MJA full text>
  • 4. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
  • 5. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998; 339: 1349-1357.
  • 6. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol And Recurrent Events trial investigators. N Engl J Med 1996; 335: 1001-1009.
  • 7. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333:1301-1307.
  • 8. National Prescribing Service. News 20 February 2002. Prescribing pointers: lipid-modifying therapy. Available at: www.nps.org.au/site.php?content=/html/news.php&news=/resources/NPS_News/news20#pp (accessed Jan 2004).

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.